Table 1 Baseline characteristics of the 20 trials used in the meta-analysis
From: Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis
Author | Year | Country | No. of patients | Stage | Assay | Follow-up (months) | NOS score |
|---|---|---|---|---|---|---|---|
Andersen [20] | 2011 | Norway | 335 | I–III | IHC | 86 | 8 |
Coelho [22] | 2014 | Portugal | 92 | I–IV | RT-PCR | NA | 6 |
Daly [27] | 2014 | USA | 197 | NA | ELISA | 60 | 7 |
Huang [28] | 2012 | China | 59 | I–III | IHC | NA | 6 |
Jiang [29] | 2015 | China | 50 | I–III | IHC | NA | 5 |
Li [30] | 2015 | China | 88 | I–IV | ELISA | NA | 5 |
Liu [31] | 2010 | China | 50 | I–IV | IHC | 60 | 7 |
Liu [32] | 2014 | China | 40 | I–IV | ELISA | 30 | 6 |
Massabeau [33] | 2008 | France | 78 | III | IHC | NA | 5 |
Park [34] | 2007 | South Korea | 110 | I–IV | ELISA | 22.1 | 8 |
Park [35] | 2009 | South Korea | 101 | I–II | ELISA | NA | 5 |
Sasaki [36] | 2012 | Japan | 110 | I–IV | RT-PCR | 60 | 8 |
Takanami [37] | 2004 | Japan | 77 | I–III | RT-PCR、IHC | 60 | 7 |
Tanaka [38] | 2002 | Japan | 236 | I–III | IHC | 60 | 8 |
Wan [39] | 2008 | China | 98 | I–IV | ELISA | 12 | 5 |
Wang [40] | 2015 | China | 114 | I–IV | IHC | NA | 7 |
Xiao [41] | 2010 | China | 41 | I–III | IHC | NA | 7 |
Xing [42] | 2003 | China | 52 | I–III | RT-PCR | NA | 7 |
Yuan [43] | 2007 | China | 46 | NA | IHC | NA | 5 |
Zhang [44] | 2008 | China | 37 | I–III | IHC | NA | 7 |